When the diagnosis is difficult to digest: severe vitamin B12 deficiency secondary to pernicious anemia mimicking life-threatening thrombotic thrombocytopenic purpura

  • Matthew SochatEmail author
  • Daniela Hermelin
  • Daniel Chakos
  • Azam Farooqui
  • Jason Lunt
  • Ara Vartanyan
  • Nishant Poddar
Case Report


Thrombotic thrombocytopenic purpura (TTP) is an uncommon yet life-threatening condition, usually marked by a classic pentad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, acute kidney injury (AKI), neurological disturbances, and fevers. Prompt recognition and treatment is essential to reduce morbidity and mortality. The rarity and variability of presentations, however, makes this a difficult diagnosis to make reliably, and in many cases, treatment is initiated empirically before the appropriate diagnostic testing is completed. After TTP and other common causes of thrombotic microangiopathy (TMA) have been excluded, evaluation for causes of “pseudo”-thrombotic microangiopathy (“pseudo”-TMA) should be pursued. Herein, we present a case of a young man with a history of previously treated hepatitis C virus (HCV) infection presenting with a syndrome concerning for TTP: MAHA, thrombocytopenia, and dizziness with gait ataxia. Disseminated intravascular coagulation (DIC) and autoimmune hemolysis were quickly ruled out, and plasma exchange was emergently initiated. Further workup identified an undetectably low vitamin B12 level with profound elevations in both homocysteine and methylmalonic acid (MMA) levels. Folate and vitamin B12 were replenished, with a rapid resolution of hemolysis and improvement in both the platelet count and hemoglobin that allowed for plasma exchange to be permanently discontinued. Further workup identified positivity of both intrinsic factor and parietal cell autoantibodies, suggesting a diagnosis of pernicious anemia. He was determined to have “pseudo”-TMA secondary to critical vitamin B12 deficiency. The patient was safely discharged home with scheduled subcutaneous vitamin B12 injections along with outpatient follow-up with both Hematology and Gastroenterology.


Pernicious anemia Vitamin B12 deficiency Thrombotic microangiopathy Microangiopathic hemolytic anemia Thrombotic thrombocytopenic purpura Intramedullary hemolysis 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158(3):323–335. CrossRefGoogle Scholar
  2. 2.
    Bendapudi PK, Li A, Hamdan A, Fry AM, Uhl L, Marques M, Kaufman R, Stowell CP, Dzik WS, Makar RS (2014) Derivation and prospective validation of a predictive score for the rapid diagnosis of thrombotic thrombocytopenic purpura: the Plasmic score. Blood 124(21):231Google Scholar
  3. 3.
    Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F (2018) The differential diagnosis and treatment of thrombotic microangiopathies. Dtsch Arztebl Int 115(19):327. Google Scholar
  4. 4.
    Noël N, Maigné G, Tertian G, Anguel N, Monnet X, Michot JM, Goujard C, Lambotte O (2013) Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency. QJM 106(11):1017–1022. CrossRefGoogle Scholar
  5. 5.
    Andrès E, Affenberger S, Federici L, Korganow AS (2006) Pseudo-thrombotic microangiopathy related to cobalamin deficiency. Am J Med 119(12):e3. CrossRefGoogle Scholar
  6. 6.
    Ballas SK, Saidi P, Constantino M (1976) Reduced erythrocytic deformability in megaloblastic anemia. Am J Clin Pathol 66(6):953–957CrossRefGoogle Scholar
  7. 7.
    Acharya U, Gau JT, Horvath W, Ventura P, Hsueh CT, Carlsen W (2008) Hemolysis and hyperhomocysteinemia caused by cobalamin deficiency: three case reports and review of the literature. J Hematol Oncol 1(1):26. CrossRefGoogle Scholar
  8. 8.
    Aslinia F, Mazza JJ, Yale SH (2006) Megaloblastic anemia and other causes of macrocytosis. Clin Med Res 4(3):236–241CrossRefGoogle Scholar
  9. 9.
    Reynolds E (2006) Vitamin B12, folic acid, and the nervous system. Lancet Neurol 5(11):949–960. CrossRefGoogle Scholar
  10. 10.
    Merino A, Cid J (2013) Very unusual presentation of pernicious anemia with schistocytes in peripheral blood. Blood 122(24):3862CrossRefGoogle Scholar
  11. 11.
    Aitelli C, Wasson L, Page R (2004) Pernicious anemia: presentations mimicking acute leukemia. South Med J 97(3):295–297. CrossRefGoogle Scholar
  12. 12.
    Hershko C, Ronson A, Souroujon M, Maschler I, Heyd J, Patz J (2006) Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood 107(4):1673–1679. CrossRefGoogle Scholar
  13. 13.
    Tadakamalla AK, Talluri SK, Besur S (2011) Pseudo-thrombotic thrombocytopenic purpura: a rare presentation of pernicious anemia. N Am J Med Sci 3(10):472–474. CrossRefGoogle Scholar
  14. 14.
    Andres E, Serraj K (2012) Optimal management of pernicious anemia. J Blood Med 3:97. CrossRefGoogle Scholar
  15. 15.
    PDQ Screening and Prevention Editorial Board (2018) Stomach (Gastric) Cancer Screening (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Online]. Available from: Accessed 21 Oct 2018
  16. 16.
    Andrès E, Loukili NH, Abdelghani MB, Noel E (2004) Pernicious anemia associated with interferon-α therapy and chronic hepatitis C infection. J Clin Gastroenterol 38(4):382CrossRefGoogle Scholar
  17. 17.
    Fabbri C, Jaboli MF, Giovanelli S, Azzaroli F, Pezzoli A, Accogli E, Liva S, Nigro G, Miracolo A, Festi D, Colecchia A (2003) Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol: WJG 9(7):1487–1490CrossRefGoogle Scholar
  18. 18.
    McMurray RW, Elbourne K (1997) Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 26(4):689–701.
  19. 19.
    Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS (2017 Aug 1) Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 67(2):263–271. CrossRefGoogle Scholar
  20. 20.
    Pol S, Pockros PJ, Pugatch D, Brau N, Landis C, Elkhashab M, Sasadeusz J, Tran A, Hu Y, Kosloski MP, Mensa F (2017) Safety and efficacy of Glecaprevir/Pibrentasvir in adults with chronic hepatitis C virus infection genotype 1 and 6 and chronic kidney disease: an integrated analysis. Gastroenterology 152(5):S1062–S1063. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hematology/OncologySt. Louis UniversitySt. LouisUSA
  2. 2.Department of PathologySt. Louis UniversitySt. LouisUSA
  3. 3.Department of Internal MedicineSt. Louis UniversitySt. LouisUSA
  4. 4.School of MedicineSt. Louis UniversitySt. LouisUSA

Personalised recommendations